James Bylund - Repligen Chief Officer
| RGEN Stock | USD 171.03 5.00 2.84% |
Insider
James Bylund is Chief Officer of Repligen
| Age | 60 |
| Address | Building 1, Waltham, MA, United States, 02453 |
| Phone | 781 250 0111 |
| Web | https://www.repligen.com |
Latest Insider Transactions
James Bylund Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Bylund against Repligen stock is an integral part of due diligence when investing in Repligen. James Bylund insider activity provides valuable insight into whether Repligen is net buyers or sellers over its current business cycle. Note, Repligen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Repligen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Bylund over a month ago Disposition of 444 shares by James Bylund of Repligen at 182.95 subject to Rule 16b-3 | ||
James Bylund over two months ago Disposition of tradable shares by James Bylund of Repligen at 195.52 subject to Rule 16b-3 | ||
James Bylund over two months ago Disposition of 820 shares by James Bylund of Repligen at 191.79 subject to Rule 16b-3 |
Repligen Management Efficiency
As of the 17th of May 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.02. At this time, Repligen's Intangible Assets are very stable compared to the past year. As of the 17th of May 2024, Net Tangible Assets is likely to grow to about 847.1 M, while Deferred Long Term Asset Charges is likely to drop about 2.2 M. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nicole Priest | Merit Medical Systems | N/A | |
| Ching leong | Becton Dickinson and | 53 | |
| Samrat Esq | Becton Dickinson and | 57 | |
| Teresa Madden | The Cooper Companies | 65 | |
| Rajwant Sodhi | ResMed Inc | 46 | |
| Fredrik Widman | Intuitive Surgical | N/A | |
| Juan Aragon | The Cooper Companies | N/A | |
| Matt Tomkin | Teleflex Incorporated | N/A | |
| Mark Drury | The Cooper Companies | 45 | |
| Francis Tan | Haemonetics | N/A | |
| Jay White | Teleflex Incorporated | 50 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Kevin Thornal | Hologic | 50 | |
| Robert Segura | West Pharmaceutical Services | N/A | |
| Amy Wakeham | ResMed Inc | N/A | |
| Paul Malenchini | Hologic | N/A | |
| Jason Treft | Merit Medical Systems | N/A | |
| FACC MD | Becton Dickinson and | N/A | |
| Elisabeth Hellmann | Hologic | 55 | |
| Josep Llorens | Haemonetics | 62 | |
| Lloyd Johnson | Haemonetics | 66 | |
Management Performance
| Return On Equity | 0.0076 | ||||
| Return On Asset | 0.006 |
Repligen Leadership Team
Elected by the shareholders, the Repligen's board of directors comprises two types of representatives: Repligen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repligen. The board's role is to monitor Repligen's management team and ensure that shareholders' interests are well served. Repligen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repligen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Gebski, Senior Chromatography | ||
| Kimberly Cornwell, General Counsel | ||
| Dianne Heiler, Senior Sustainability | ||
| James Bylund, Chief Officer | ||
| Kola Otitoju, Senior Development | ||
| Stephen Tingley, VP Sales | ||
| Jaime Humara, Senior Marketing | ||
| Jon Snodgres, Chief Officer | ||
| Olivier Loeillot, President Officer | ||
| Rachel Goodrich, VP Marketing | ||
| Ralf Kuriyel, Senior Vice President - Research & Development | ||
| Neil Whitfield, Vice Sales | ||
| Leslie Galvin, Global Resources | ||
| Mark Salerno, VP Analytics | ||
| Keith Robinson, Chief Officer | ||
| Sondra Newman, Global Relations | ||
| Jason Garland, Chief Officer | ||
| Anthony Hunt, President CEO, Director | ||
| Craig Harrison, VP Analytics |
Repligen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repligen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0076 | ||||
| Return On Asset | 0.006 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 9.79 B | ||||
| Shares Outstanding | 55.88 M | ||||
| Shares Owned By Insiders | 6.58 % | ||||
| Shares Owned By Institutions | 93.42 % | ||||
| Number Of Shares Shorted | 4.42 M | ||||
| Price To Earning | 154.58 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.Note that the Repligen information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Repligen Stock analysis
When running Repligen's price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.26 | Revenue Per Share 10.892 | Quarterly Revenue Growth (0.17) | Return On Assets 0.006 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.